HealthDay News — More than one-quarter of patients with systemic lupus erythematosus (SLE) have metabolic syndrome (MetS), according to a review published online in the International Journal of Rheumatic Diseases.
Chong Sun, from First Hospital of China Medical University in Shenyang, and colleagues conducted a systematic review and meta-analysis assessing the prevalence of MetS in patients with SLE.
The researchers found that 47 studies (8367 subjects), published between 2006 and 2016, showed a pooled prevalence of MetS in patients with SLE of 0.26.
Twenty-four studies (2744 cases and 3028 controls) found that SLE patients had high risk of MetS (odds ratio, 1.88).
“The systematic review and meta-analysis demonstrated the prevalence of MetS in patients with SLE was 26% and the patients with SLE were more prone to having MetS than the control population,” the authors write.
Sun C, Qin W, Zhang YH, et al. Prevalence and risk of metabolic syndrome in patients with systemic lupus erythematosus: A meta-analysis. Int J Rheum Dis. 2017;20(8):917-928.